Navidea Biopharma (NAVB) Tops Q3 EPS by 2c; Revenue Beats

November 3, 2016 8:45 AM EDT
Get Alerts NAVB Hot Sheet
Trade NAVB Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.47 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment